The combinatorial treatment with pharmacological inhibitors of EGFR such as gefitinib, erlotinib, and PI3K/AKT pathway has exhibited a synergistic anti‐tumorigenic potential in treating basal subtypes of TNBCs, resulting in reduced metastasis of breast cancer cells.44 Here, EGFR is linked to breast carcinoma.